![Stephan Toutain](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stephan Toutain
Directeur des opérations chez
PDS BIOTECHNOLOGY CORPORATION
Fortune : - $ au 30/06/2026
Profil
Stephan Toutain is Chief Operating Officer at PDS Biotechnology Corp.
since 2024.
Former roles include Senior Vice President-Operations at Anavex Life Sciences Corp.
from 2018 to 2024, Chief Commercial Officer at Interleukin Genetics, Inc. from 2016 to 2017, Head-Global Commercial Development at Sarepta Therapeutics, Inc. from 2014 to 2015, and General Manager at Alexion Pharmaceuticals, Inc. from 2009 to 2011.
Education includes graduate studies at Nancy-Université and an MBA from The University of North Carolina at Charlotte.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Postes actifs de Stephan Toutain
| Sociétés | Poste | Début |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Directeur des opérations | 01/05/2024 |
Anciens postes connus de Stephan Toutain
| Sociétés | Poste | Fin |
|---|---|---|
| ANAVEX LIFE SCIENCES CORP. | Directeur des opérations | 01/04/2024 |
| INTERLEUKIN GENETICS, INC | Corporate Officer/Principal | 01/08/2017 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2015 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2011 |
Formation de Stephan Toutain
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
32
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Sarepta Therapeutics, Inc.
 Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
Interleukin Genetics, Inc.
 Interleukin Genetics, Inc. Pharmaceuticals: MajorHealth Technology Develops personalized health products | Health Technology |
Anavex Life Sciences Corp.
 Anavex Life Sciences Corp. BiotechnologyHealth Technology Engages in the development of innovative drug compounds | Health Technology |
Nancy-Université
 Nancy-Université Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of North Carolina at Charlotte
 The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PDS Biotechnology Corp.
 PDS Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Develops clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers | Health Technology |
Choisissez Zonebourse 
